Seiji Mabuchi

7.4k total citations · 1 hit paper
192 papers, 5.7k citations indexed

About

Seiji Mabuchi is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Seiji Mabuchi has authored 192 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Obstetrics and Gynecology, 77 papers in Reproductive Medicine and 53 papers in Molecular Biology. Recurrent topics in Seiji Mabuchi's work include Endometrial and Cervical Cancer Treatments (86 papers), Ovarian cancer diagnosis and treatment (65 papers) and Cervical Cancer and HPV Research (22 papers). Seiji Mabuchi is often cited by papers focused on Endometrial and Cervical Cancer Treatments (86 papers), Ovarian cancer diagnosis and treatment (65 papers) and Cervical Cancer and HPV Research (22 papers). Seiji Mabuchi collaborates with scholars based in Japan, United States and Canada. Seiji Mabuchi's co-authors include Tadashi Kimura, Hiromasa Kuroda, Kenjiro Sawada, Ryoko Takahashi, Yuri Matsumoto, Tadashi Kimura, Kae Hashimoto, Masahide Ohmichi, Tomoyuki Sasano and Hirohisa Kurachi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Seiji Mabuchi

184 papers receiving 5.6k citations

Hit Papers

The PI3K/AKT/mTOR pathway as a therapeutic target in ovar... 2015 2026 2018 2022 2015 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
    2015 335 citations Seiji Mabuchi, Hiromasa Kuroda et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiji Mabuchi Japan 42 2.4k 1.6k 1.5k 1.4k 1.1k 192 5.7k
Elena Ioana Braicu Germany 40 2.1k 0.9× 1.7k 1.0× 2.3k 1.6× 925 0.7× 1.2k 1.1× 303 5.4k
Masashi Takano Japan 38 1.8k 0.8× 1.2k 0.7× 2.6k 1.8× 1.5k 1.1× 575 0.5× 255 5.5k
Aikou Okamoto Japan 36 4.4k 1.9× 1.9k 1.2× 1.7k 1.1× 1.1k 0.8× 3.1k 2.8× 267 8.0k
Rouba Ali‐Fehmi United States 39 1.2k 0.5× 811 0.5× 1.3k 0.9× 1.6k 1.1× 874 0.8× 152 4.2k
Noriomi Matsumura Japan 41 2.5k 1.0× 3.7k 2.3× 2.1k 1.4× 1.2k 0.9× 1.4k 1.2× 212 7.9k
Robert M. Wenham United States 33 2.3k 1.0× 1.4k 0.8× 1.4k 1.0× 632 0.5× 1.4k 1.2× 158 4.7k
Kenjiro Sawada Japan 40 2.7k 1.1× 1.3k 0.8× 789 0.5× 478 0.3× 1.5k 1.3× 137 5.0k
Stéphanie Lheureux Canada 27 1.8k 0.8× 1.6k 1.0× 1.7k 1.2× 526 0.4× 1.1k 1.0× 153 4.3k
Gilad Ben‐Baruch Israel 39 1.4k 0.6× 995 0.6× 1.7k 1.2× 1.3k 0.9× 657 0.6× 152 4.7k
Akihiro Nawa Japan 33 1.5k 0.6× 1.5k 0.9× 720 0.5× 418 0.3× 614 0.5× 111 3.8k

Countries citing papers authored by Seiji Mabuchi

Since Specialization
Citations

This map shows the geographic impact of Seiji Mabuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiji Mabuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiji Mabuchi more than expected).

Fields of papers citing papers by Seiji Mabuchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiji Mabuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiji Mabuchi. The network helps show where Seiji Mabuchi may publish in the future.

Co-authorship network of co-authors of Seiji Mabuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Seiji Mabuchi. A scholar is included among the top collaborators of Seiji Mabuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiji Mabuchi. Seiji Mabuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Mabuchi, Seiji, Naoko Komura, Tomoyuki Sasano, et al.. (2023). Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer. Current Oncology. 30(11). 9428–9436. 1 indexed citations
4.
Matsuzaki, Shinya, Yutaka Ueda, Satoko Matsuzaki, et al.. (2023). Relationship between Abnormal Placenta and Obstetric Outcomes: A Meta-Analysis. Biomedicines. 11(6). 1522–1522. 6 indexed citations
5.
Matsuzaki, Shinya, Yutaka Ueda, Satoko Matsuzaki, et al.. (2023). Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors. Cancers. 15(18). 4470–4470. 2 indexed citations
6.
Mabuchi, Seiji, Yuri Matsumoto, Ayako Miyazaki, et al.. (2022). Iliac artery-enteric fistula developed during bevacizumab-containing chemotherapy for recurrent cervical cancer: A case report and literature review. Gynecologic Oncology Reports. 40. 100938–100938. 2 indexed citations
7.
8.
Mabuchi, Seiji, Tomoyuki Sasano, & Naoko Komura. (2021). Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer. Cells. 10(2). 329–329. 33 indexed citations
9.
Mabuchi, Seiji & Tomoyuki Sasano. (2021). Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers. Cells. 10(5). 1073–1073. 12 indexed citations
10.
Komura, Naoko, Seiji Mabuchi, Kenjiro Sawada, et al.. (2021). Subsequent menstrual disorder after spontaneous menarche in Turner syndrome. Clinical Endocrinology. 95(1). 163–168. 5 indexed citations
11.
Sasano, Tomoyuki, Seiji Mabuchi, Katsumi Kozasa, et al.. (2018). The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations. Clinical Cancer Research. 24(16). 4018–4029. 40 indexed citations
12.
Yokoi, Eriko, Seiji Mabuchi, Kotaro Shimura, et al.. (2018). Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer. Investigational New Drugs. 37(5). 818–827. 20 indexed citations
13.
Nakamura, Koji, Kenjiro Sawada, Yasuto Kinose, et al.. (2016). Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Molecular Cancer Research. 15(1). 78–92. 183 indexed citations
14.
Mabuchi, Seiji, et al.. (2016). Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients. Journal of Gynecologic Oncology. 28(1). e15–e15. 31 indexed citations
15.
Kinose, Yasuto, Kenjiro Sawada, Hiroshi Makino, et al.. (2015). IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment. Molecular Cancer Therapeutics. 14(4). 909–919. 23 indexed citations
16.
Hisamatsu, Takeshi, Seiji Mabuchi, Yuri Matsumoto, et al.. (2013). Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics. 12(7). 1367–1377. 37 indexed citations
17.
Matsuo, Koji, Todd Sheridan, Kiyoshi Yoshino, et al.. (2012). Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Medicine. 1(2). 156–164. 36 indexed citations
18.
Mabuchi, Seiji, Takeshi Hisamatsu, Masami Hayashi, et al.. (2011). The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary. Clinical Cancer Research. 17(13). 4462–4473. 29 indexed citations
19.
Mabuchi, Seiji, Deborah A. Altomare, Denise C. Connolly, et al.. (2007). RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. Cancer Research. 67(6). 2408–2413. 156 indexed citations
20.
Hayakawa, Jun, Masahide Ohmichi, Keiichi Tasaka, et al.. (2002). Regulation of the PRL Promoter by Akt through cAMP Response Element Binding Protein. Endocrinology. 143(1). 13–22. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elena Ioana Braicu Breakdown of academic impact, for papers by Masashi Takano Breakdown of academic impact, for papers by Aikou Okamoto Breakdown of academic impact, for papers by Rouba Ali‐Fehmi Breakdown of academic impact, for papers by Noriomi Matsumura Breakdown of academic impact, for papers by Robert M. Wenham Breakdown of academic impact, for papers by Kenjiro Sawada Breakdown of academic impact, for papers by Stéphanie Lheureux Breakdown of academic impact, for papers by Gilad Ben‐Baruch Breakdown of academic impact, for papers by Akihiro Nawa
Rankless by CCL
2026